Accessibility Menu
Jasper Therapeutics logo

Jasper Therapeutics(NASDAQ) JSPR

Market Cap$17.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 YearN/A
1 Year-79%
1 Month+42%
$0.63
+3.98%
+0.02Today
Jasper Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.612026-08-03
Jasper Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.67%USD 0.692026-07-27
1 month+41.56%USD 0.432026-07-02
3 month-37.26%USD 0.972026-05-05
Year to date-66.87%USD 1.832025-12-31
1 year-78.95%USD 2.882025-08-01
3 year-96.04%USD 15.302023-08-04
Since inception-99.38%USD 98.202020-01-10

Jasper Therapeutics Financials at a Glance

Market Cap

$17.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$55.73M

EPS (TTM)

-$3.23

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$0.63

Volume

246,701.499

Open

$0.61

Previous Close

$0.61

Daily Range

$0.59 - $0.65

52-Week Range

$0.32 - $3.14

Estimated Earnings Date

Aug 12, 2026

JSPR News

Foolcom-Featured.png

Jasper Reports Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 13, 2025
excited-invetor-trading-stocks

Why Jasper Therapeutics Stock Is Jumping Today

Cory RenauerOct 13, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jasper Therapeutics

Jasper Therapeutics develops therapies for stem cell transplants and gene therapies. Its products aim to improve treatment outcomes for patients needing these advanced medical procedures. The company focuses on making these therapies safer and more accessible.

Products and Services

JSP191: A conditioning antibody in clinical trials for stem cell therapy preparation.

Engineered Stem Cells: Developing products to enhance gene-edited stem cell grafts.

Gene Therapy Solutions: Focused on ex vivo gene therapy to improve transplantation outcomes.

Conditioning Agents: Designed to prepare patients for hematopoietic stem cell transplantation.

Stem Cell Engineering: Innovations to expand the use of stem cell therapies.

Clinical Development Programs: Ongoing trials to validate new therapeutic approaches.

Growth and Expansion

Exclusive licensing agreements with Amgen and Stanford University for competitive product development.

Initiated Phase 1b/2a studies, including BEACON and SPOTLIGHT, to expand clinical programs.

Expanded research collaborations to enhance therapeutic pipeline and market reach.

What Makes Jasper Special

Jasper Therapeutics leverages the SCF/c-Kit pathway to target mast-cell driven diseases. This focus provides a unique approach in the biotechnology sector.

Five Things You Need to Know

Reported a net loss of $71.3 million for 2024.

Cash and cash equivalents stood at $71.6 million as of December 2024.

Accumulated deficit reached $240.9 million by the end of 2024.

Jasper has not yet generated revenue from product sales.

Ongoing need for additional funding to support development programs.

Bottom Line

Jasper Therapeutics is advancing in stem cell and gene therapy innovation. Its strategic partnerships and clinical trials position it for future growth.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

22

CEO

Jeet Mahal, MBA

Website

www.jaspertherapeutics.com

Headquarters

Redwood City, CA 94065, US

JSPR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-523.04%

Return on Capital

-1494.95%

Return on Assets

-263.09%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

28.08M

Volume

246.70K

Avg. Volume

1.37M

Financials (TTM)

Gross Profit

-$21.00K

Operating Income

-$73.03M

EBITDA

-$54.94M

Operating Cash Flow

-$68.87M

Capital Expenditure

-$7.00K

Free Cash Flow

-$68.87M

Cash & ST Invst.

$14.14M

Total Debt

$757.00K

Jasper Therapeutics Performance Analysis

Jasper Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Jasper Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Jasper Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.33-61.6%
20232023-12-31USD -6.18-40.2%
20242024-12-31USD -4.89-20.9%
20252025-12-31USD -3.95-19.1%
Jasper Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-23.4%
Q32025-09-3035.1%
Q42025-12-3147.8%
Q12026-03-3187.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$21.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$17.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$773.85K

N/A

Employees

22

N/A

Net Income

-$1.17M

+94.5%

EBITDA

-$1.15M

+94.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.14M

-71.0%

Total Debt

$757.00K

-70.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$757.00K

-58.7%

Return on Assets

-2.63%

N/A

Return on Invested Capital

-5.99%

N/A

Free Cash Flow

-$14.55M

+36.3%

Operating Cash Flow

-$14.55M

+36.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NXTCNextCure, Inc.
$5.65+28.41%
CELUCelularity Inc.
$0.77+16.48%
PSTVPlus Therapeutics, Inc.
$3.87+0.00%
BTAIBioXcel Therapeutics, Inc.
$0.88+3.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$160.87+0.28%
AMIXAutonomix Medical
$11.18+2.06%
NOKNokia
$10.01+0.07%
INTCIntel
$100.10+0.10%

Questions About JSPR

What is the current price of Jasper Therapeutics?

Jasper Therapeutics is trading at $0.62 per share.

What is the 52-week range for Jasper Therapeutics?

Over the past 52 weeks, Jasper Therapeutics has traded between $0.32 and $3.14.

How much debt does Jasper Therapeutics have?

As of the most recent reporting period, Jasper Therapeutics reported total debt of $757.00K.

How much cash does Jasper Therapeutics have on hand?

Jasper Therapeutics reported $14.14M in cash and cash equivalents in its most recent financial results.

What is Jasper Therapeutics’s dividend yield?

Jasper Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services